On March 4, 2021 Polaris Pharmaceuticals reported it is Based on the current interim analysis data, it is estimated that the overall success rate of the final trial will be over 80% (Press release, Polaris Pharmaceuticals, MAR 4, 2021, View Source [SID1234576082]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on the current observations, it is estimated that the overall survival at the end of the trial will be statistically greater than 80% for CP, and the trial committee recommended that the Phase III clinical trial continue according to the original application plan.

This means that the ADI PEG-20 treatment group will have a statistically significant chance of exceeding the overall survival of the control group by more than 80% after continued patient enrollment in the Phase III clinical trial, according to the experts.